#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Metastases to central nervous system Granulomatosis with polyangiitis Short-bowel syndrome Hydrocephalus Chondrodystrophy Familial haemophagocytic lymphohistiocytosis Metabolic disorder Antiphospholipid antibodies Sjogren's syndrome Bronchiolitis Alveolar proteinosis Gastrooesophageal cancer Follicular lymphoma stage II Choroid melanoma Glomerulonephritis chronic More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis I – Diagnostics Primary mediastinal large B-cell lymphoma – Diagnostics Indolent systemic mastocytosis – Treatment Malignant fibrous histiocytoma – Life with Disease Von Willebrand’s disease – Basic Information Stevens-Johnson syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Alagille syndrome – Trials in Disease Myelodysplastic syndrome with excess blasts – Trials in Disease Hereditary angioedema – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Treprostinil Sodium ZALFERMIN Zinc Oxide Roginolisib Olodaterol TETANUS TOXOID Doxycycline Gentamicin Nms-03305293 Levofloxacin Hemihydrate Alternaria Alternata (402) Glucocorticoids Cetrelimab Tuparstobart Trehalose Dihydrate (Ph.eur.) Tasipimidine Crizotinib Desoximetasone ACARBOSE Petosemtamab More therapies…

    Learn about Your Condition

    Hand dermatitis Methylmalonic acidaemia Muscular dystrophy Cancer fatigue Bone marrow failure Small intestine carcinoma Synovial sarcoma metastatic Endometrial cancer Pancreatic fistula Primary hypercholesterolaemia Pancreatitis acute Acute myocardial infarction Cholangiocarcinoma Bronchostenosis Prostatitis Escherichia coli More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hippokration Hospital

Hippokration Hospital

Vxofwmfcxog Szohkx Aohixe 1hwu Ajiiixl 1yt 2nt Gpnlgj

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Imatinib Mesilate
    Finland France Germany Greece Hungary Italy +7

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    France Greece Hungary Portugal Spain Sweden

  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sarilumab
    • Prednisone
    Austria Belgium Czechia France Germany Greece +3

  • A study to evaluate the safety of OMN6 in patients with pneumonia caused by Acinetobacter baumannii bacteria.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pneumonia bacterial
    Investigated Drugs:
    • Saline
    Greece Hungary Italy

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Epoetin Alfa
    • Elritercept
    Belgium Bulgaria France Germany Greece Hungary +8

  • A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Filgotinib
    Belgium Bulgaria Czechia France Germany Greece +4

  • A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Tenecteplase
    Bulgaria Greece Hungary Norway Romania Spain

  • A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Estonia France +10
1 2 3 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!